Bio-Path Holdings, Inc. ( BPTH ) shares are trading higher Friday after the company announced interim results from its Phase 2 study of prexigebersen in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia.

The Details:

Bio-Path ( BPTH ) said the data presented showed prexigebersen continues to be well-tolerated and demonstrated efficacy results in two reporting cohorts including evaluable newly diagnosed AML patients and evaluable refractory/relapsed AML patients, both of which exceeded outcomes with frontline therapy.

“It was a pleasure to present these compelling data to an audience of European oncologists who treat AML patients and understand the continued great need for new therapeutic options,” said Peter Nielsen, CEO of Bio-Path ( BPTH ). 

“Given that our study is being conducted in the U.S., this encore presentation is an important step towards educating global oncology leaders on the benefits of prexigebersen and its potential to be another tool in their fight against AML.”

Related News: What’s Going On With Longeveron Stock?

BPTH Stock Prediction 2024:

Equity research can be a valuable source of information for learning about a company's fundamentals. Analysts create financial models based on the fundamentals and expected future earnings of a company to arrive at a price target and recommendation for the stock.

Shares of Bio-Path Holdings ( BPTH ) have an average 1-year price target of $40, representing an expected upside of 1900%.

Because of differences in assumptions, analysts can arrive at very different price targets and recommendations. No analysts have bearish recommendations on Bio-Path ( BPTH ), while 2 analysts have bullish ratings. The street high price target from Roth MKM is $40.

BPTH Price Action: According to Benzinga Pro, Bio-Path ( BPTH ) shares are up 13.5% at $2.27 at the time of publication Friday.

Image: Shutterstock